Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic

D. Leonardi Vinci, A. Meccio, A. Provenzani, ME. Faggiano, N. Miljković, D. Makridaki, P. Horák, P. Polidori

. 2022 ; 29 (e1) : e23-e29. [pub] 20210222

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010852
E-zdroje Online Plný text

NLK PubMed Central od 2016
Europe PubMed Central od 2016 do Před 1 rokem
ProQuest Central od 2012-02-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 2012-02-01 do Před 6 měsíci

Odkazy

PubMed 33619027
DOI 10.1136/ejhpharm-2020-002633
Knihovny.cz E-zdroje

OBJECTIVE: To create an informatics supportive tool, which can assist healthcare professionals in estimating potential requirements for essential drug supplies to respond to the current SARS-CoV-2 pandemic based on epidemiological forecasting. METHODS: The tool was based on a Susceptible-Infected-Removed (SIR) epidemiological model in which the population is divided into three compartments and transmission parameters are specified to define the rate at which people move between stages. Appropriate data entry was guaranteed by the creation of structured guided paths. The drugs needed for the forecasted patients were estimated according to a list of critical care drugs compiled by consulting previous published scientific works, national and international guidelines. For each drug, an estimation was made of the percentage average ICU uptake for each therapeutic group and active principle. RESULTS: The tool consists of a Microsoft Excel template that is based on the initial epidemiological situation, the non-pharmaceutical interventions applied, the risk of hospitalisation based on the population age distribution, and the hospital beds available. The tool provides a forecast of which patients with COVID-19 will need to be treated in a hospital setting. The number of patients is used to estimate the drugs needed based on the average daily dose and the treatment length of each drug. The possibility of editing the type of distribution (exponential or linear) of the number of patients at the beginning of the analysis, the percentage adherence with non-pharmaceutical interventions and their delayed effect, and all the key epidemiological parameters make the estimation tailorable to different clinical contexts and needs. CONCLUSIONS: This model might be an effective supporting tool that could be easily implemented within the workflow of health professionals. All the information reported in this paper could be useful in developing new strategies to tackle the COVID-19 pandemic.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010852
003      
CZ-PrNML
005      
20220506131503.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/ejhpharm-2020-002633 $2 doi
035    __
$a (PubMed)33619027
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Leonardi Vinci, Daniele $u School of Specialization in Hospital Pharmacy, University of Palermo, Palermo, Sicilia, Italy daniele.leo93@gmail.com $1 https://orcid.org/0000000343833726
245    14
$a The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic / $c D. Leonardi Vinci, A. Meccio, A. Provenzani, ME. Faggiano, N. Miljković, D. Makridaki, P. Horák, P. Polidori
520    9_
$a OBJECTIVE: To create an informatics supportive tool, which can assist healthcare professionals in estimating potential requirements for essential drug supplies to respond to the current SARS-CoV-2 pandemic based on epidemiological forecasting. METHODS: The tool was based on a Susceptible-Infected-Removed (SIR) epidemiological model in which the population is divided into three compartments and transmission parameters are specified to define the rate at which people move between stages. Appropriate data entry was guaranteed by the creation of structured guided paths. The drugs needed for the forecasted patients were estimated according to a list of critical care drugs compiled by consulting previous published scientific works, national and international guidelines. For each drug, an estimation was made of the percentage average ICU uptake for each therapeutic group and active principle. RESULTS: The tool consists of a Microsoft Excel template that is based on the initial epidemiological situation, the non-pharmaceutical interventions applied, the risk of hospitalisation based on the population age distribution, and the hospital beds available. The tool provides a forecast of which patients with COVID-19 will need to be treated in a hospital setting. The number of patients is used to estimate the drugs needed based on the average daily dose and the treatment length of each drug. The possibility of editing the type of distribution (exponential or linear) of the number of patients at the beginning of the analysis, the percentage adherence with non-pharmaceutical interventions and their delayed effect, and all the key epidemiological parameters make the estimation tailorable to different clinical contexts and needs. CONCLUSIONS: This model might be an effective supporting tool that could be easily implemented within the workflow of health professionals. All the information reported in this paper could be useful in developing new strategies to tackle the COVID-19 pandemic.
650    12
$a COVID-19 $7 D000086382
650    _2
$a péče o pacienty v kritickém stavu $7 D003422
650    _2
$a hospitalizace $7 D006760
650    _2
$a lidé $7 D006801
650    12
$a pandemie $7 D058873
650    _2
$a SARS-CoV-2 $7 D000086402
655    _2
$a časopisecké články $7 D016428
700    1_
$a Meccio, Adriano $u Chemical Engineering, University of Palermo, Palermo, Sicilia, Italy
700    1_
$a Provenzani, Alessio $u Clinical Pharmacy, ISMETT, Palermo, Italy
700    1_
$a Faggiano, Maria Ernestina $u Pharmacy, AOU Policlinico, Bari, Puglia, Italy
700    1_
$a Miljković, Nenad $u Hospital Pharmacy, Institute of Orthopaedic Surgery "Banjica", Belgrade, Serbia
700    1_
$a Makridaki, Despina $u Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
700    1_
$a Horák, Petr $u Hospital Pharmacy, Motol University Hospital, Praha, Praha, Czech Republic
700    1_
$a Polidori, Piera $u Clinical Pharmacy, ISMETT, Palermo, Italy $1 https://orcid.org/0000000184969908
773    0_
$w MED00200143 $t European journal of hospital pharmacy : science and practice $x 2047-9956 $g Roč. 29, č. e1 (2022), s. e23-e29
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33619027 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131455 $b ABA008
999    __
$a ok $b bmc $g 1788793 $s 1162050
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 29 $c e1 $d e23-e29 $e 20210222 $i 2047-9956 $m European journal of hospital pharmacy $n Eur J Hosp Pharm $x MED00200143
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace